医療ロボット市場 (2025 - 2035)

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical and engineering journals, clinical safety publications, and authoritative healthcare technology organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) 510(k) clearances and Premarket Approval (PMA) databases, European Medicines Agency (EMA) medical device regulations, International Federation of Robotics (IFR) Medical Robotics Committee, IEEE Robotics and Automation Society (RAS) standards and publications, International Organization for Standardization (ISO) Technical Committee 299 (Robotics), International Electrotechnical Commission (IEC) 80601-2-77 standards, American College of Surgeons (ACS) clinical guidelines, Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) robotics committee reports, National Institutes of Health (NIH) National Library of Medicine (clinical trials registry for robotic interventions), World Health Organization (WHO) Global Health Observatory medical device statistics, OECD Health Statistics (healthcare technology adoption metrics), Eurostat Healthcare Database (medical technology utilization), and national ministry of health medical device regulatory reports from key markets including Japan's Ministry of Health, Labour and Welfare (MHLW), China's National Medical Products Administration (NMPA), and Health Canada. These sources were utilized to collect robotic surgical procedure statistics (Da Vinci, Mazor X, NAVIO installations and utilization rates), regulatory clearance timelines, clinical safety and efficacy studies (surgical outcomes, adverse event reports), healthcare infrastructure adoption trends, and competitive intelligence for surgical robotic systems, rehabilitation robots, pharmacy automation, and emergency response robotics.

In order to gather qualitative information and verify market hypotheses, supply-side and demand-side stakeholders were contacted during the primary research process using quantitative surveys and structured interviews. Medical robotic system manufacturers, component suppliers (haptic sensors, robotic arms, AI software developers), healthcare OEM partners, and chief executive officers, vice presidents of engineering and research and development, heads of regulatory affairs and quality assurance, chief commercial officers, and product marketing directors were among the supply-side sources. Board-certified general surgery, orthopedics, cardiology, neurology, and urology surgeons, chiefs of surgery and medical directors from academic medical centers and tertiary care hospitals, procurement directors and value analysis committees from integrated delivery networks (IDNs), administrators of ambulatory surgical centers (ASCs), clinical directors of rehabilitation centers, and pharmacy operations managers were among the demand-side sources.

Primary research validated market segmentation across surgical robotics (soft tissue, orthopedic, neurosurgery), rehabilitation robotics (exoskeletons, prosthetics, assistive devices), and hospital automation; confirmed product development roadmaps and pipeline timelines; and gathered insights on surgical adoption patterns (conversion rates from laparoscopic to robotic), capital equipment purchasing cycles, maintenance service contracts, consumables attachment rates, and reimbursement pathways (CPT codes for robotic-assisted procedures).

Primary Respondent Breakdown:

By Designation: C-level Primaries (30%), Director Level (35%), Others (35%)

By Region: North America (40%), Europe (25%), Asia-Pacific (28%), Rest of World (7%)

Global market valuation was derived through comprehensive revenue mapping, installed base analysis, and procedure volume calculations specific to robotic-assisted interventions. The methodology included:

Identification of 40+ key manufacturers and system integrators across North America (Intuitive Surgical, Medtronic, Stryker, Zimmer Biomet, Accuray), Europe (Smith & Nephew, CMR Surgical, KUKA Health), Asia-Pacific (Mazor Robotics, MicroPort Scientific, Tianjin Sino), and emerging markets

Product mapping across surgical robotic systems (multi-port, single-port, open console), rehabilitation robots (wearable exoskeletons, end-effector devices), noninvasive radiosurgery systems (CyberKnife, Gamma Knife), hospital & pharmacy automation, and imaging/navigation robotic platforms

Component segmentation analysis including capital equipment (robotic consoles, arms, vision systems), consumables (instruments, accessories, single-use attachments), and services (maintenance contracts, training, software subscriptions)

Analysis of reported and modeled annual revenues specific to robotic surgery portfolios, rehabilitation device divisions, and automation segments

Coverage of manufacturers representing 75-80% of global medical robotics market share in 2024

Extrapolation using bottom-up approach (installed base of robotic systems by region × average annual utilization rates per console × ASP per procedure for instruments and services) combined with top-down validation (manufacturer reported revenue cross-verification) to derive segment-specific valuations for surgical applications (laparoscopy, orthopedics, neurology, cardiology), rehabilitation settings, and hospital logistics automation